{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-101892","form_type":"8-K","ticker":"TOVX","cik":"0000894158","company_name":"Theriva Biologics, Inc.","filed_at":"2024-09-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.212706+00:00","generated_at":"2026-05-31T02:39:44.078411+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Theriva Biologics achieves target enrollment of 92 patients in VIRAGE Phase 2b trial for VCN-01 in pancreatic cancer","bullets":["Target enrollment of 92 evaluable patients (46 per arm) achieved across 15 sites in Spain and USA within 21 months.","VCN-01 is a systemically-administered oncolytic adenovirus with FDA Orphan Drug and Fast Track Designations for metastatic PDAC.","VCN-01 treatment arm: two IV doses (1x10^13 vp/patient) administered ~3 months apart, 7 days prior to gem/nab-paclitaxel cycles.","Phase 1 data for single VCN-01 dose plus SoC (n=6): 83% overall response rate, median PFS 6.3 months, OS 20.8 months.","Company plans regulatory engagements to discuss next steps, including potential interim data analysis."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-101892","json":"https://secwatch.observer/filing/0001104659-24-101892.json","markdown":"https://secwatch.observer/filing/0001104659-24-101892.md","text":"https://secwatch.observer/filing/0001104659-24-101892.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/894158/000110465924101892/0001104659-24-101892-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/894158/000110465924101892/tm2424516d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T02:39:44.078411+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}